All News
Bone Density in Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a burden on the bones—both literally and diagnostically. The disease’s dual nature, marked by chronic inflammation and abnormal new bone formation, complicates the assessment of bone health.
Read Article
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g
@synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X
Finally good news in Sjogrens disease.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Why are vaccine Abs maintained after CAR-T
-depletion of pathogenic #Abs are dampened/eliminated
Clonal repetoire expansion
Remission=naive B cell pop'n
Reset immune system sparing memory cells
vs ?not all pathogenic cells eliminated in tissue
#ACR25 @RheumNow @ACRheum
#26S21 https://t.co/jb3dD5Ssip
Janet Pope Janetbirdope ( View Tweet)
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x
Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD .
I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
From Fitbit to first diagnosis: AI is rewriting the RA playbook
Two studies presented at this year’s #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://t.co/8AwBZkyZIW
Dr. John Cush RheumNow ( View Tweet)
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases
At #ACR25, the ACR presented new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, https://t.co/nJjtTMHnD3
Dr. John Cush RheumNow ( View Tweet)
Day 1 Recap: #ACR25 Highlights
Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they discuss highlights and key takeaways from the Day 1 Recap on Sunday, October 26th.
https://t.co/Kq8TDBLUYZ https://t.co/TNM8ZAji9w
Dr. John Cush RheumNow ( View Tweet)
CAR T
Which cells to target
What patients & what disease
When is right time
In vivo (new) ex vivo
Premeds immune suppression
What to use, ?if anything
Cons
Is it safe
?long term effectiveness
What is failure rate
ICANs and other side effects
#ACRBest #ACR25 @RheumNow #26S21 https://t.co/TUSJh1hrPr https://t.co/JiqYzgBmYP
Links:
Janet Pope Janetbirdope ( View Tweet)
Needle in a haystack
What T cell to target for #autoimmune diseases
T cell repetoires (TCR) not all are sequenced and many can exist to present antigens
Diff scales of approaches
Implications CAR-T
CD19
CD20
BCMA
Treg
HLAB27
etc!
#ACR25 @ACRheum @RheumNow
Alok Joglekar
#26S08 https://t.co/Qgw8Akz1xk
Links:
Janet Pope Janetbirdope ( View Tweet)
Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC
TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN.
AE rates comparable.
TAC - AKI & tremor
MMF - leucopenia
reassuring data.more tx options.
#ACR25 @RheumNow Abs2697 https://t.co/16Fd8zE5dL
sheila RHEUMarampa ( View Tweet)
So what's been tried for ICANS, knowing that it's unlikely that one therapy will fix all of it?
@CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/10wdkrH29s
Links:
David Liew drdavidliew ( View Tweet)
Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA?
Pretty good so far - but obviously will be under enormous scrutiny when we are looking at diseases with good existing therapies
#ACR25 ABST0471 @RheumNow https://t.co/xXyzOwLvx8
David Liew drdavidliew ( View Tweet)
2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1)
🔹All pts (n=10) met SRI-4 by wk24
🔹DORIS remission: 5 (wk24), 6 (wk36–48)
🔹Residual proteinuria (n=4); renal bx (n=3) showed resolved IC deposits & inflammation
🔹CRS Grade 1 (n=6); no ICANS
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
What does the FDA regulatory approach look like for CAR-T and T cell engages right now?
The FDA session at #ACR25 gave some clues @RheumNow https://t.co/wHNnNTrXaE
Links:
David Liew drdavidliew ( View Tweet)
LB23: Regulate-RA- ongoing Phase 1 trial of autologous CAR-Tregs in refractory RA (no lymphodepletion)
🔹 4/6 pts had ↓ DAS28-CRP by wk 4 with rapid onset & ↓ joint counts at dose level 2
🔹 Synovial biopsies to date showed ↓ inflammatory score post-tx
@RheumNow #ACR25 https://t.co/JMBbLIEmJG
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
LB04: Another approach to CAR-T, CD20+/BCMA bispecific CAR-T in refractory proliferative LN:
🔹100% discontinued biologics & IS at follow-up
🔹Renal response ~78%
🔹CRS mostly Grade 1–2 (~70%); ≥Grade 3 AEs = transient & hematologic
@RheumNow #ACR25 https://t.co/oNK4wtLGYV
Links:
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#ACR25 Please find my blog on update and progress of clinical trials in #Sjogren #SjD @RheumNow
https://t.co/u8pxZ5FeBX https://t.co/KAnRo3Zqnz
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstract 1563: Ongoing Phase 1/2 trial of Rese-cel CAR-T in systemic sclerosis
🔹Pt with severe skin involvement showed improvement in mRSS (42→34), PFTs & nailfold capillaroscopy at 6 mo
🔹Grade 2 CRS, no ICANS or DLT reported
Early but exciting findings
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
While post-CAR-T CRS might be semi-familiar for rheumatologists, ICANS is a new concept to get our heads around, and one which is far from heterogenous.
@CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/qX2jKMG2oB
David Liew drdavidliew ( View Tweet)
